Antioxidant and Anti-Inflammatory Properties of Melatonin in Patients with Type 2 Diabetes Mellitus with Periodontal Disease Under Non-Surgical Periodontal Therapy: A Double-Blind, Placebo-Controlled Trial

• Main Authors: Zare Javid A, Hosseini SA, Gholinezhad H, Moradi L, Haghighi-zadeh MH, Bazyar H
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-03-01
• Series: Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
• Subjects: type 2 diabetes mellitus; periodontal disease; melatonin; inflammatory markers; antioxidant enzymes
• Online Access: https://www.dovepress.com/antioxidant-and-anti-inflammatory-properties-of-melatonin-in-patients--peer-reviewed-article-DMSO
• ISSN: 1178-7007

Ahmad Zare Javid,1,2 Seyed Ahmad Hosseini,1,2 Hassan Gholinezhad,2 Leila Moradi,3 Mohammad Hosein Haghighi-zadeh,4 Hadi Bazyar1,5 1Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 2Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 3Health Research Institute, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 4Department of Biostatistics, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; 5Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranCorrespondence: Hadi BazyarNutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranTel [phone]Email [e-mail] and Aim: The imbalance between pro-oxidant and antioxidant systems often leads to further oxidative damage in the pathogenesis of both diabetes and periodontal disease. This study aimed to investigate the antioxidant and anti-inflammatory properties of melatonin in type 2 diabetes mellitus (T2DM) patients with periodontal disease (PD) under non-surgical periodontal therapy (NSPT).Materials and Methods: In this double-blind clinical trial study, 50 T2DM patients with PD were randomly allocated to intervention and control groups and received 250 mg/day (2 tablets) either melatonin or placebo 1 h before bedtime for 8 weeks. The NSPT was performed for all patients in both groups at the beginning of the study. The serum levels of interleukin-1b (IL-1b), malondialdehyde (MDA), total antioxidant capacity (TAC), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) were measured pre- and post-intervention.Results: Supplementation with melatonin in adjunct to NSPT significantly increased the serum levels of TAC, SOD, CAT, and GPx in the intervention group (P = 0.02, 0.008, 0.004 and 0.004, respectively). The mean changes of SOD, CAT, and GPx were significantly (P = 0.02, 0.04 and 0.04, respectively) greater in the intervention group compared with the control group. Also, after adjusting for confounding factors, the results did not change in terms of significance (P < 0.05). After the intervention, serum levels of MDA and IL-1b were significantly reduced in the intervention group (P < 0.001 and P = 0.008, respectively). The intervention group exhibited lower mean changes of MDA compared with the control group, and these changes were statistically significant (P = 0.008). In addition, after adjusting for confounding factors, the results did not change in terms of significance.Conclusion: The adjunctive effects of melatonin and NSPT may improve inflammatory and antioxidant parameters in T2DM patients with PD.Keywords: type 2 diabetes mellitus, periodontal disease, melatonin, inflammatory markers, antioxidant enzymes